Scancell Holdings plc, the developer of therapeutic cancer and infectious disease vaccines based on its patented Immunobody® platform, is pleased to announce the interim results for the six month period ended 31st October 2010.
Successful progression of SCIB1, Scancell's lead vaccine for melanoma, which entered clinical trials in June 2010
Raised £2.5 million in April 2010 with new and current shareholders
Moved from PLUS to AIM in July 2010
Secured licensing agreements with:
the National Institutes of Health (an agency of the United States Department of Health and Human Services); and
Cancer Research Technology Ltd (Cancer Research UK's commercialisation and development arm)
Entered strategic collaborations with:
ImmuneRegen BioSciences, Inc.®; and
immatics biotechnologies GmbH
Four patients recruited to date for the clinical trials
Approval obtained to open a fourth UK patient recruitment site and to expand the patient population in the Phase I part of the study, to include all patients with Stage III and Stage IV malignant melanoma
Escalation of the dose and recruitment of the next group of patients in SCIB1 trial approved by the Cohort Review Committee
For further information contact:
Scancell Holdings Plc
Professor Lindy Durrant
+ 44 (0)207 245 1100
Kirsty Corcoran/Adam Reynolds
+44 (0)207 245 1100
Zeus Capital - Nominated Adviser/Joint Broker
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512
Matrix Corporate Capital LLP - Joint Broker
Robert Naylor/Stephen Waterman
After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.
Fri, 21 Jun 2019 08:21:00
Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.
The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.
Thu, 13 Jun 2019 09:53:00
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Thu, 13 Jun 2019 06:31:00
Sign up to our newsletter to stay up to date with Scancell